Keyphrases
Randomized Double-blind
100%
Cystic Fibrosis
100%
Phase II Trial
100%
Once-daily
100%
Genotype
85%
Ivacaftor
71%
Absolute Change
57%
Cystic Fibrosis Transmembrane Conductance Regulator
57%
Monotherapy
42%
Domain Scores
42%
Sweat Chloride
42%
Cystic Fibrosis Questionnaire-Revised
42%
F508del
42%
Placebo
28%
Adverse Events
28%
Safety Profile
28%
Once-daily Dosing
28%
Clinical Trials
14%
Cough
14%
Headache
14%
Serious Adverse Events
14%
Phase III Clinical Trial
14%
Efficacy Endpoint
14%
Change from Baseline
14%
Treatment Discontinuation
14%
Rash
14%
Tolerability
14%
Lung Function
14%
Respiratory Symptoms
14%
Proof of Concept Study
14%
Phase II Clinical Trial
14%
Pulmonary Exacerbation
14%
Active Control
14%
Chloride Transport
14%
Sputum
14%
Minimal Function
14%
Gating mutation
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cystic Fibrosis
100%
Deutivacaftor
100%
Ivacaftor
62%
Cystic Fibrosis Transmembrane Conductance Regulator
50%
Clinical Trial
37%
Monotherapy
37%
Adverse Event
37%
Placebo
25%
Coughing
12%
Headache
12%
Rash
12%
Tolerability
12%